Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials

References

• Ho PM, Tsai TT, Maddox TM, et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes 2010;3:261-6
   PubMed Web of Science ®Google Scholar
• Kubica A, Kasprzak M, Siller-Matula J, et al. Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. Eur J Pharmacol 2014;742:47-54
   PubMed Web of Science ®Google Scholar
• Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010;103:363-75
   PubMed Web of Science ®Google Scholar
• Legrand D, Legrand V. Adherence to antiplatelet therapy in patients with coronary artery disease. Rev Med Liege 2010;65:304-10
   PubMedGoogle Scholar
• Navarese EP, Verdoia M, Schaffer A, et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 2011;104:561-9
   PubMed Web of Science ®Google Scholar
• Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:273-82
   PubMed Web of Science ®Google Scholar
• Tantry US, Jeong YH, Navarese EP, et al. Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. Expert Rev Cardiovasc Ther 2013;11:447-62
   PubMedGoogle Scholar
• Kubica A, Kozinski M, Grzesk G, et al. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis 2011;32:459-66
   PubMed Web of Science ®Google Scholar
• Kozinski M, Bielis L, Wisniewska-Szmyt J, et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets 2011;22:579-87
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Delle-Karth G, Lang IM, et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. J Thromb Haemost 2012;10:529-42
   PubMed Web of Science ®Google Scholar
• Kubica A, Koziński M, Grześk G, Goch A. Clinical significance of interactions between clopidogrel and proton pump inhibitors. Kardiol Pol 2011;69:610-16
   PubMed Web of Science ®Google Scholar
• Karaźniewicz-Łada M, Danielak D, Główka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin Pharmacother 2012;13:663-83
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009;3:e123-30
   PubMedGoogle Scholar
• Canpolat U, Yorgun H, Atalar E. Simultaneous subacute thrombosis of bare metal coronary stents in two different arteries early after clopidogrel cessation. Cardiol J 2012;19:309-13
   PubMed Web of Science ®Google Scholar
• Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-2
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Zghal FM, Amri A, Mourali MS, et al. Bare metal stent thrombosis in patients with acute coronary syndrome. Circ J 2012;76:634-40
   PubMed Web of Science ®Google Scholar
• Qureshi Z, Hobson AR. Clopidogrel “resistance”: where are we now? Cardiovasc Ther 2013;31:3-11
   PubMed Web of Science ®Google Scholar
• Rafferty M, Walters MR, Dawson J. Anti-platelet therapy and aspirin resistance – clinically and chemically relevant? Curr Med Chem 2010;17:4578-86
   PubMed Web of Science ®Google Scholar
• Steinwender C, Hartenthaler B, Lambert T, et al. Incidence of stent thrombosis in patients with drug eluting stents and short-term dual antiplatelet therapy. EuroIntervention 2009;4:593-9
   PubMed Web of Science ®Google Scholar
• Kubica A, Kasprzak M, Obonska K, et al. Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction. Pharmacology 2015;95:50-8
   PubMed Web of Science ®Google Scholar
• Ho PM, Lambert-Kerzner A, Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med 2014;174:186-93
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhao Z, McCollam P, et al. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin 2011;27:633-41
   PubMed Web of Science ®Google Scholar
• Pallares MJ, Powers ER, Zwerner PL, et al. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother 2009;43:259-67
   PubMed Web of Science ®Google Scholar
• Latry P, Martin-Latry K, Lafitte M, et al. Dual antiplatelet therapy after myocardial infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. EuroIntervention 2012;7:1413-19
   PubMed Web of Science ®Google Scholar
• Nordstrom BL, Simeone JC, Zhao Z, et al. Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. Am J Cardiovasc Drugs 2013;13:263-71
   PubMed Web of Science ®Google Scholar
• Ferreira-González I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year. J Am Coll Cardiol 2012;60:1333-9
   PubMed Web of Science ®Google Scholar
• Ferreira-González I, Marsal JR, Ribera A, et al. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation 2010;122:1017-25
   PubMed Web of Science ®Google Scholar
• Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012;15;109:214-18
   PubMed Web of Science ®Google Scholar
• Melloni C, Alexander KP, Ou FS, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009;104:175-81
   PubMed Web of Science ®Google Scholar
• Mayer F, Bargagli AM, Belleudi V, et al. Socioeconomic position and appropriate antiplatelet therapy after percutaneous coronary intervention: a population-based cohort study in Rome (Lazio Region, Central Italy). Epidemiol Prev 2014;38:123-31
   PubMed Web of Science ®Google Scholar
• Collins SD, Torguson R, Gaglia MA Jr, et al. Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 2010;122:1085-90
   PubMed Web of Science ®Google Scholar
• Shimony A, Zahger D, Ilia R, et al. Impact of the community’s socioeconomic status on characteristics and outcomes of patients undergoing percutaneous coronary intervention. Int J Cardiol 2010;144:379-82
   PubMed Web of Science ®Google Scholar
• Whitley HP. Monetary value of a prescription assistance program service in a rural family medicine clinic. J Rural Health 2011;27:190-5
   PubMed Web of Science ®Google Scholar
• Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care 2010;16:290-7
   PubMed Web of Science ®Google Scholar
• Burke JP, Sander S, Shah H, et al. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin 2010;26:1023-30
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood) 2010;29:1995-2001
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J 2014;167:51-8
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Avorn J, Glynn RJ, et al. Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97
   PubMed Web of Science ®Google Scholar
• Kulik A, Desai NR, Shrank WH, et al. Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial. Circulation 2013;128(11 Suppl 1):S219-S25
   PubMed Web of Science ®Google Scholar
• Sengstock D, Vaitkevicius P, Salama A, Mentzer RM. Under-prescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence. Drugs Aging 2012;29:93-103
   PubMed Web of Science ®Google Scholar
• Roth GA, Morden NE, Zhou W, et al. Clopidogrel use and early outcomes among older patients receiving a drug eluting coronary artery stent. Circ Cardiovasc Qual Outcomes 2012;5:103-12
   PubMed Web of Science ®Google Scholar
• Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9
   PubMed Web of Science ®Google Scholar
• Muntner P, Mann DM, Woodward M, et al. Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol 2011;108:822-7
   PubMed Web of Science ®Google Scholar
• Dehghani P, Chopra V, Bell A, et al. Southern Saskatchewan ticagrelor registry experience. Patient Prefer Adherence 2014;8:1427-35
   PubMed Web of Science ®Google Scholar
• Garavalia L, Garavalia B, Spertus JA, Decker C. Exploring patients’ reasons for discontinuance of heart medications. J Cardiovasc Nurs 2009;24:371-9
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Kereiakes DJ, Mauri L, et al. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. JACC Cardiovasc Interv 2015;8:404-10
   PubMed Web of Science ®Google Scholar
• Rossini R, Baroni M, Musumeci G, Gavazzi A. Oral antiplatelet therapy after drug-eluting stent implantation: adherence and side-effects. J Cardiovasc Med (Hagerstown) 2013;14:81-90
   PubMed Web of Science ®Google Scholar
• Armero S, Bonello L, Berbis J, et al. Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes. Am J Cardiol 2011;108:1710-13
   PubMed Web of Science ®Google Scholar
• Kovacic JC, Lee P, Karajgikar R, et al. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary “real-world” practice. J Interv Cardiol 2012;25:482-92
   PubMed Web of Science ®Google Scholar
• Simeone JC, Molife C, Marrett E, et al. One-year post-discharge resource utilization and treatment patterns of patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with ticagrelor or prasugrel. Am J Cardiovasc Drugs 2015;15:337-50
   PubMed Web of Science ®Google Scholar
• Gaubert M, Laine M, Richard T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. Int J Cardiol 2014;173:120-1
   PubMed Web of Science ®Google Scholar
• Belchikov YG, Koenig SJ, Dipasquale EM. Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy 2013;33:882-7
   PubMed Web of Science ®Google Scholar
• Parodi G, Storey RF. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care 2015;4:555-60
   PubMed Web of Science ®Google Scholar
• Spinler SA. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. Pharmacotherapy 2009;29:812-21
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Stavrou K, Koniari I, et al. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thromb Haemost 2014;112:551-7
   PubMed Web of Science ®Google Scholar
• Larmore C, Effron MB, Molife C, et al. “Real-world” comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States. Catheter Cardiovasc Interv 2015: published online 18 November 2015, doi: 10.1002/ccd.26279
   PubMed Web of Science ®Google Scholar
• Vrijens B, Claeys MJ, Legrand V, et al. Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Br J Clin Pharmacol 2014;77:746-55
   PubMed Web of Science ®Google Scholar
• Thim T, Johansen MB, Chisholm GE, et al. Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 2014;14:100
   PubMed Web of Science ®Google Scholar
• Decker C, Garavalia L, Garavalia B, Spertus JA. Clopidogrel-taking behavior by drug-eluting stent patients: discontinuers versus continuers. Patient Prefer Adherence 2008;2:167-75
   PubMedGoogle Scholar
• Cruden NL, Din JN, Janssen C, et al. Delay in filling first clopidogrel prescription after coronary stenting is associated with an increased risk of death and myocardial infarction. J Am Heart Assoc 2014;3:e000669
   PubMed Web of Science ®Google Scholar
• Bally K, Buechel RR, Buser P, et al. Discontinuation of secondary prevention medication after myocardial infarction – the role of general practitioners and patients. Swiss Med Wkly 2013;143:w13896
   PubMed Web of Science ®Google Scholar
• Syed IA, Riaz A, Ryan A, Reilly MO. Secondary prevention for coronary artery disease: are we following the guidelines? Ir J Med Sci 2010;179:535-7
   PubMed Web of Science ®Google Scholar
• Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction – a hospital registry–primary care linked cohort (MINAP–GPRD). Eur Heart J 2011;32:2376-86
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kandzari DE. Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Neth Heart J 2007;15:148-50
   PubMed Web of Science ®Google Scholar
• Davlouros P, Gizas V, Stavrou K, et al. DES thrombosis related to antiplatelet therapy noncompliance: a consequence of the Greek financial crisis. Int J Cardiol 2013;168:4497-9
   PubMed Web of Science ®Google Scholar
• Fallis BA, Dhalla IA, Klemensberg J, Bell CM. Primary medication non-adherence after discharge from a general internal medicine service. PLoS One 2013;8:e61735
   PubMed Web of Science ®Google Scholar
• Kronish IM, Rieckmann N, Shimbo D, et al. Aspirin adherence, aspirin dosage, and C-reactive protein in the first 3 months after acute coronary syndrome. Am J Cardiol 2010;106:1090-94
   PubMed Web of Science ®Google Scholar
• Walter PN, Tsakiris DA, Romanens M, et al. Antiplatelet resistance in outpatients with monitored adherence. Platelets 2014;25:532-8
   PubMed Web of Science ®Google Scholar
• Serebruany V, Cherala G, Williams C, et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J 2009;158:925-32
   PubMed Web of Science ®Google Scholar
• Siller-Matula J, Lang IM, Neunteufl T, et al. Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. PLoS One 2014;22:e102701
   Web of Science ®Google Scholar
• Alexopoulos D, Xanthopoulou I, Stavrou K, et al. Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy. Can J Cardiol 2013;29:1743.e13-4
   PubMed Web of Science ®Google Scholar
• Kubica A, Obońska K, Kasprzak M, et al. Prediction of high risk of non-adherence to antiplatelet treatment. Kardiol Pol 2015: published online 23 June 2015, doi: 10.5603/KP.a2015.0117
   PubMed Web of Science ®Google Scholar
• Moussa ID, Colombo A. Antiplatelet therapy discontinuation following drug-eluting stent placement: dangers, reasons, and management recommendations. Catheter Cardiovasc Interv 2009;74:1047-54
   PubMed Web of Science ®Google Scholar
• Garavalia L, Ho PM, Garavalia B, et al. Clinician–patient discord: exploring differences in perspectives for discontinuing clopidogrel. Eur J Cardiovasc Nurs 2011;10:50-5
   PubMed Web of Science ®Google Scholar
• Rymer J, McCoy LA, Thomas L, et al. Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. Am J Cardiol 2014;114:1479-84
   PubMed Web of Science ®Google Scholar
• Hamrosi K, Dickinson R, Knapp P, et al. It’s for your benefit: exploring patients’ opinions about the inclusion of textual and numerical benefit information in medicine leaflets. Int J Pharm Pract 2013;21:216-25
   PubMedGoogle Scholar
• Bottorff MB, Nutescu EA, Spinler S. Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. Pharmacotherapy 2007;27:1145-62
   PubMed Web of Science ®Google Scholar
• Kubica A. Health Education and the Efficacy of Antiplatelet Therapy in Myocardial Infarction Survivors on the Background of Selected Factors. Toruń, Poland: Wydawnictwo Naukowe Uniwersytetu Mikołaja Kopernika, 2012
   Google Scholar
• Kubica A, Pufal J, Moczulska B, et al. Effectiveness of health education in patients hospitalized in the department of cardiology. Psychiatria w Praktyce Ogólnolekarskiej 2005;2:61-8
   Google Scholar
• Calvert AB, Kramer JM, Anstrom KJ, et al. Patient-focused intervention to improve long term adherence to evidence-based medications: a randomized trial. Am Heart J 2012;163:657-65
   PubMed Web of Science ®Google Scholar
• Hedegaard U, Kjeldsen LJ, Pottegard A, et al. Multifaceted intervention including motivational interviewing to support medication adherence after stroke/transient ischemic attack: a randomized trial. Cerebrovasc Dis Extra 2014;4:221-34
   PubMedGoogle Scholar
• Palacio AM, Uribe C, Hazel-Fernandez L. Can phone-based motivational interviewing improve medication adherence to antiplatelet medications after a coronary stent among racial minorities? A randomized trial. J Gen Intern Med 2015;30:469-75
   PubMed Web of Science ®Google Scholar
• Schwartz LM, Woloshin S, Welch HG. Using a drug facts box to communicate drug benefits and harms: two randomized trials. Ann Intern Med 2009;150:516-27
   PubMed Web of Science ®Google Scholar
• Park LG, Howie-Esquivel J, Chung ML, Dracup K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ Couns 2014;94:261-8
   PubMed Web of Science ®Google Scholar
• Schwalm JD, Ivers NM, Natarajan MK, et al. Cluster randomized controlled trial of Delayed Educational Reminders for Long-term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI). Am Heart J 2015;170:903-13
   PubMed Web of Science ®Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79
   PubMed Web of Science ®Google Scholar
• Jung JA, Kim TE, Kim JR, et al. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study. Clin Ther 2013;35:985-94
   PubMed Web of Science ®Google Scholar